Table 2.
Indication of treatment of ALK-positive metastatic small-cell lung cancer. TKI: tyrosine kinase inhibitor, ALK: anaplastic lymphoma kinase, NTRK: neurotrophic receptor tyrosine kinase, Gen.: Generation.
| TKI | Gen. | Posology | Target | FDA Approval for Treatment of ALK-Positive Metastatic NSCLC | Indication for Treatment of ALK-Positive Metastatic NSCLC |
|---|---|---|---|---|---|
| Alectinib | 2 | 600 mg × 2/day | ALK | Yes | First-line |
| Brigatinib | 2 | 90 mg × 1/day for 7 days then 180 mg × 1/day |
ALK | Yes | First-line |
| Ceritinib | 2 | 450 mg × 1/day | ALK | Yes | ALK TKI agent based on the resistance profile |
| Crizotinib | 1 | 250 mg × 2/day | ALK ROS1 |
Yes | |
| Lorlatinib | 3 | 100 mg × 1/day | ALK ROS1 |
Yes | ALK TKI agent based on the resistance profile |